title: Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis.
authors.affiliation: Hämatologie/Onkologie, Medizinische Klinik 1, UK S-H, Campus Lübeck, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Stölting
authors.forename: T
authors.initials: T
authors.lastname: Klink
authors.forename: C
authors.initials: C
authors.lastname: Bela
authors.forename: C
authors.initials: C
authors.lastname: Engels
authors.forename: T
authors.initials: T
authors.lastname: Wagner
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D051379:Mice; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; C003726:trofosfamide